Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
NCT05908786 · Hoffmann-La Roche · PHASE1/PHASE2 · terminated · last registry update 2026-09-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was closed early as the sponsor decided not to continue development of certain treatment combinations.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Phase 3 first posted: Boehringer Ingelheim, Obrixtamig + Ezabenlimab (NCT07929051)
- 2026-11-10Also stopped (suspended): National Cancer Institute (NCI), azacytidine + carboplatin (NCT06694454)
- 2026-11-10Results posted on the registry: William Zeitler, Durvalumab + Pharmacological ascorbate (NCT06083454)
- 2026-11-10Also stopped (terminated): William Zeitler, Durvalumab + Pharmacological ascorbate (NCT06083454)
- 2026-11-09Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04294810)
- 2026-11-05Results posted on the registry: University of Maryland, Baltimore, Combination Radiation, Immunotherapy, Surgery (NCT03116529)
- 2026-11-05Also stopped (terminated): University of Maryland, Baltimore, Combination Radiation, Immunotherapy, Surgery (NCT03116529)
- 2026-11-04Also stopped (terminated): AHS Cancer Control Alberta, Avelumab and Radical radiotherapy (NCT03737721)
- 2026-11-02Also stopped (suspended): National Cancer Institute (NCI), Atezolizumab + Cetuximab (NCT01810913)
- 2026-11-02Phase 3 first posted: Merck Sharp & Dohme LLC, Gocatamig + Durvalumab (NCT07908537)
- 2026-10-29Also stopped (suspended): National Cancer Institute (NCI), Atezolizumab (NCT04402788)
- 2026-10-26Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A1811 Injection + Adebrelimab Injection (NCT07896005)
- 2026-10-26Phase 3 first posted: West China Hospital, Adebrelimab (SHR-1316) + chemotherapy + Adebrelimab (NCT07895238)
- 2026-10-20Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + DEC-205/NY-ESO-1 Fusion Protein CDX-1401 (NCT03206047)
- 2026-10-20Also stopped (terminated): National Cancer Institute (NCI), Atezolizumab + DEC-205/NY-ESO-1 Fusion Protein CDX-1401 (NCT03206047)
- 2026-10-16Phase 3 first posted: AstraZeneca, FLOT Chemotherapy + Durvalumab (NCT07877818)
- 2026-10-14Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Tiragolumab (NCT05715281)
- 2026-10-09Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody + Placebo Comparator (NCT03456063)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Atezolizumab (NCT04214262)
- 2026-10-06Results posted on the registry: Washington University School of Medicine, Paclitaxel + Carboplatin AUC (NCT03916419)
- 2026-10-01Results posted on the registry: PrECOG, LLC., Durvalumab + Standard Chemotherapy (NCT04334759)
- 2026-10-01Results posted on the registry: Coherus Oncology, Inc., Casdozokitug + Atezolizumab (NCT05359861)
- 2026-10-01Also stopped (terminated): Coherus Oncology, Inc., Casdozokitug + Atezolizumab (NCT05359861)
- 2026-09-28Results posted on the registry: Hoffmann-La Roche, Atezolizumab (NCT04660344)
- 2026-09-25Results posted on the registry: AstraZeneca, Neoadjuvant Olaparib monotherapy group + Neoadjuvant combination therapy with olaparib plus durvalumab (NCT05498155)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision